Significant Ownership of JOHNSON & JOHNSON

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for JOHNSON & JOHNSON focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager 2 identity fields
Signature and title
/s/ Marc Larkins - Marc Larkins/Secretary
Location
New Brunswick, NJ

Follow Filing Activity

Follow JOHNSON & JOHNSON and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Significant Ownership of JOHNSON & JOHNSON

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CVRX CVRx, Inc. Common Stock, $0.01 par value 15% $28,578,928 4,024,861 JOHNSON & JOHNSON 31 Dec 2025
RAPP Rapport Therapeutics, Inc. Common Stock, $0.001 par value 4.9% $53,000,690 1,784,517 JOHNSON & JOHNSON 30 Sep 2025
RLYB Rallybio Corporation Common Stock, $0.0001 par value 2.9% $88,683 152,901 Johnson & Johnson 31 Mar 2026

Schedules 13D/G Reported by JOHNSON & JOHNSON:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .